DOCSLIB.ORG

Fatal Hepatitis During Epstein-Barr Virus Reactivation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fatal Hepatitis During Epstein-Barr Virus Reactivation European Review for Medical and Pharmacological Sciences 2003; 7: 107-109 Fatal hepatitis during Epstein-Barr virus reactivation B. CACOPARDO, G. NUNNARI, M.T. MUGHINI, S. TOSTO, F. BENANTI, L. NIGRO Department of Internal Medicine and Medical Specialities, Unit of Infectious Diseases, University of Catania - Catania (Italy) Abstract. – Fulminant hepatitis by Case Report Epstein-Barr virus is a rare event which is predominantly due to primary infection. We report a rare case of fatal hepatic failure due A 19-year-old male student was admitted to Epstein-Barr virus reactivation in a 19- to the Department of Infectious Diseases year-old boy who was taking oral steroids. (University of Catania) presenting with fa- Transaminase peak and the fulminant course of the disease began soon after steroid inter- tigue and jaundice. Past clinical history in- ruption. Epstein-Barr virus reactivation was cluded acute hepatitis A at the age of 7. At diagnosed on the basis of past clinical history the age of 14, infectious mononucleosis had of heterophile-positive infectious mononucle- been diagnosed on the basis of prolonged osis, a high titer of IgG anti Epstein-Barr viro- fever, pharyngitis, splenomegaly and positive capsidic antigen, slight elevation of anti-viro- Paul-Bunnel Davidson test. capsidic IgM, a high titer of anti-EA IgG anti- Two months before the onset of jaundice, bodies and elevated viral load in serum mea- sured by polymerase chain reaction. It is con- the patient complained of severe arthralgias cluded that Epstein-Barr virus should be con- with joint swelling and fever. A local practi- sidered as a possible etiological agent of ful- tioner diagnosed rheumatoid arthritis on minant hepatitis. clinical grounds. The patient began therapy Key Words: with methylprednisolone at a dosage of 40 mg/day orally and a prompt remission of Epstein-Barr virus, Reactivation, Steroids, Fulminant hepatitis. symptoms was achieved. Steroid treatment was scheduled as 40 mg/day for 20 days fol- lowed by 20 mg/day for a further 20 days. Thirty days after beginning steroid treat- ment, the patient developed fatigue, general Introduction malaise and became icteric. He did not pre- sent fever or sore throat. The liver and spleen were palpable at 6 cm and 4 cm below Infectious mononucleosis caused by the costal margin, respectively. No lym- Epstein-Barr virus (EBV) infection is usual- phadenopathy was found. Laboratory test re- ly accompanied by a mild, self-limiting he- sults revealed ALT 916 IU/L, total bilirubi- patic dysfunction. EBV-related liver failure naemia 14 mg/dl and prothrombin activity in previously healthy individuals is very rare 80%. Total white blood cell count was 9.700 although it has been reported in immuno- mm3 (neutrophils 38%, lymphocytes 32%, compromised patients during primary EBV monocytes 30%) and platelets were infection1,2. Cases of fulminant hepatic fail- 108.000/mm3. Serum immunoglobulins were ure (FHF) induced by primary EBV infec- normal. Rheumatoid factor was negative. tion have frequently been described in chil- CD4+ T cell count was 887/mm3 and CD8+ dren affected with the X-linked lymphopro- count was 1416/mm3. Abdominal ultrasound liferative syndrome2,3. We report a very rare scan showed mild hepatosplenomegaly with case of fulminant hepatitis induced by the no evident focal lesions. Serum HbsAg, anti- reactivation of EBV during immunosup- Hbc IgM and anti-HCV antibody were nega- pressive therapy. tive. Anti-Cytomegalovirus; anti Coxsachie 107 B. Cacopardo, G. Nunnari, M.T. Mughini, S. Tosto, F. Benanti, L. Nigro virus A and B and anti-Toxoplasma IgG and serum immunoglobulin levels2; (3) post-trans- IgM antibodies were also negative. Serum plant lymphoproliferative disorders and non- HCV RNA was negative as determined by Hodgkin’s lymphoma2,3. polymerase chain reaction (PCR). HIV 1 The profile of the case presented does not serology was negative. Ceruloplasmin was fit any of the above mentioned conditions. normal and non-organ specific serum autoan- This was a case of fulminant hepatitis in a pa- tibodies were negative. Bone marrow aspi- tient who had no evidence of long-standing rate showed hypercellularity with an increase immunosuppression and was healthy before in atypical lymphoid cells, but with no evi- initiating corticosteroids. As far as we know, dence of histiocytic hyperplasia or prominent this is the first report of fulminant hepatitis haemophagocytosis. The titre of IgG anti- due to the reactivation of latent EBV. Past EBV viral capsid antigen (VCA) antibodies clinical history of infectious mononucleosis, was 1/2560; IgM anti-EBV VCA and IgG an- the high titer of IgG anti-Epstein-Barr viro- tibodies against early antigen (EBV-EA) capsid antigen, the slight elevation of specific were positive at a titre of 1/320. Finally, EBV IgM and anti-EA IgG antibodies support the DNA was found both in unfractionated hypothesis of viral reactivation in this case5, whole blood and in serum using both qualita- which is further confirmed by the elevated vi- tive BamHI-W-repeat PCR and quantitative ral load in serum6. competitive PCR (viral load: 200,000 A peculiar clinical characteristic of this copies/ml). The day after admission, methyl- case was the absence of signs and symptoms prednisolone assumption was interrupted. typical of EBV infection such as lym- Three days later, both ALT and bilirubin lev- phadenopathy and pharyngitis. Overt hepati- els peaked at 4810 U/I and 24 mg/dl, respec- tis due to EBV in the absence of other signs tively. Prothrombin activity fell below 20%. of infection is uncommon in young patients, On day 7 following admission, ALT level de- whereas this is more commonly seen in pa- creased to 358 U/I and signs of hepatic en- tients older than 402,4. cephalopathy appeared. The patient was ad- The reactivation of EBV was probably in- mitted to the intensive care unit. He received duced by high-dose steroid treatment or, less intravenous acyclovir, fresh frozen plasma, probably however, due to autoimmune arthri- omeprazole, lactulose and oral neomycin. On tis. Autoimmune diseases, immunosuppres- day 10 of hospitalization, encephalopathy in- sive drugs, neoplasms, CMV and HIV-1 have creased to grade 3 and the patient died be- been reported elsewhere as underlying causes fore liver transplant could be performed. of EBV reactivation7-10. In particular, steroids are a common cause of EBV reactivation from latency. It remains to be established whether steroids may reactivate EBV directly Discussion by promoting viral replication or alternative- ly by down-regulating the ability of the mem- Infectious mononucleosis is usually a be- ory T-cell response to control the latent virus. nign disease. Severe complications such as The immunopathogenic mechanisms respon- splenic rupture, encephalitis, myocarditis, sible for liver damage in EBV infection are as pericarditis and hepatitis are seen in fewer yet not clearly specified. EBV produces no than 1% of all cases and fatalities are even direct cytopathic effects in hepatocytes2, al- rarer4. Fulminant hepatitis may represent a though sporadic infection of hepatocytes by common cause of death in different types of EBV has been demonstrated11. EBV infec- EBV-induced disorders: (1) spontaneous fatal tion of T cells has been hypothesized to pre- infectious mononucleosis, whose clinical fea- cipitate autoaggressive cytotoxicity12. tures are related to primary EBV infection Moreover, a cytotoxic T-cell response against and characterized either by typical symptoms EBV-antigens on infected B cells or hepato- and signs of infectious mononucleosis or by cytes has been put forward as being responsi- evidence of haemophagocytosis in bone mar- ble for liver necrosis in a pattern similar to row aspirate2,3; (2) X-linked lymphoprolifera- that reported for Hepatitis B virus liver dam- tive disease which is a familial syndrome age2. In this case, the sudden withdrawal of mostly involving children with abnormal steroids could have played a triggering role 108 Fatal hepatitis during Epstein-Barr virus reactivation by inducing an immunologic rebound direct- 6) STEVENS SJ, VERVOORT MB, VAN DEN BRULE AJ, ed at EBV-infected cells. Studies of with- MEENHORST PL, MEJIER CJ, MIDDLEDORP JM. Monitoring of Epstein Barr DNA load in peripheral drawal from corticosteroids have, in fact, al- blood by quantitative competitive PCR. J Clin ready described episodes of hepatic decom- Microbiol 1999; 37: 2852-2857. pensation or worsening of hepatic histology 7) AALTO SM, LINNAVUORI K, PELTOLA H, et al. in patients with acute or chronic viral hepati- Immunoreactivation of Epstein-Barr virus due to tis13. The present study provides evidence Cytomegalovirus primary infection. J Med Virol that the use of steroids may favour the reacti- 1998; 56: 186-191. vation of EBV from a latent status. Finally, 8) RAHMAN MA, KINGSLEY LA, ATCHINSON RW, et al. EBV should be considered as a possible etio- Reactivation of Epstein-Barr virus during early in- logical agent of fulminant hepatitis also in the fection with human immunodeficiency virus. J absence of the typical signs of infectious Clin Microbiol 1991; 29: 1215-1220. mononucleosis. 9) PALANDUZ A, YILDIMARK Y, T EHLAN L, et al. Fulminant hepatic failure and autoimmune hemolytic anemia associated with Epstein Barr virus infection. J Infect 2002; 45: 96-98. 10) OGAWA J, KOIKE R, SUGIHARA T, et al. An autopsied case of chronic active Epstein Barr virus infection References complicated in systemic lupus erythematous and antiphospholipid antibody syndrome. Nihon 1) Shaw N.J, Evans JHC. Liver failure and Epstein- Rinsho Meneki Gakkai Kaishi 2002; 25: 458-465. Barr virus infection. Arch Dis Child, 1988; 63: 432-445. 11) PAPATHEODORIDIS GV, DELLADETSIMA JK, KAVALLIEROU L, KAPRANOS N, TASSOPOULOS NC. Fulminant hepatitis 2) MARKIN RS. Manifestations of Epstein-Barr virus due to Epstein Barr virus infection. J Hepatol associated disorders in liver. Liver 1994; 14: 1-13. 1995; 23: 348-350. 3) WICK MJ, WORONZOFF-DASHKOFF KP, MCGLENNEN RC.
Load more

Recommended publications
  • Immunogenicity and Efficacy Testing in Chimpanzees of an Oral Hepatitis B Vaccine Based on Live Recombinant Adenovirus
    Proc. Natl. Acad. Sci. USA Vol. 86, pp. 6763-6767, September 1989 Medical Sciences Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus (adenovirus animal model/adenovirus-vectored vacdnes) MICHAEL D. LUBECK*, ALAN R. DAVIS*, MURTY CHENGALVALA*, ROBERT J. NATUK*, JOHN E. MORIN*, KATHERINE MOLNAR-KIMBER*, BRUCE B. MASON*, BHEEM M. BHAT*, SATOSHI MIZUTANI*, PAUL P. HUNG*, AND ROBERT H. PURCELLO *Wyeth-Ayerst Research, Biotechnology and Microbiology Division, P.O. Pox 8299, Philadelphia, PA 19101; and tLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 Contributed by Robert H. Purcell, May 30, 1989 ABSTRACT As a major cause of acute and chronic liver which, because oftheir wide prior usage, are good candidates disease as well as hepatocellular carcinoma, hepatitis B virus as vectors. Other less well-characterized small animal models (HBV) continues to pose significant health problems world- for human adenoviruses have been occasionally reported wide. Recombinant hepatitis B vaccines based on adenovirus (11-13) but are likewise nonpermissive for Ad4 and Ad7 vectors have been developed to address global needs for infections (unpublished data). An early study of animal effective control of hepatitits B infection. Although consider- species including nonhuman primates indicated that human able progress has been made in the construction ofrecombinant adenoviruses do not induce acute respiratory disease in adenoviruses that express large amounts of HBV gene prod- monkeys or chimpanzees following intranasal inoculations ucts, preclinical immunogenicity and efficacy testing of candi- (14). Serological data, however, indicated that such experi- date vaccines has remained difficult due to the lack ofa suitable mental infections occasionally induced anti-adenovirus anti- animal model.
    [Show full text]
  • Hepatitis B Fast Facts Everything You Need to Know in 2 Minutes Or Less!
    Hepatitis B Foundation Cause for a Cure www.hepb.org Hepatitis B Fast Facts Everything you need to know in 2 minutes or less! Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus (HBV) that attacks liver cells and can lead to liver failure, cirrhosis (scarring) or cancer of the liver. The virus is transmitted through contact with blood and bodily fluids that contain blood. Most people are able to fight off the hepatitis B infection and clear the virus from their blood. This may take up to six months. While the virus is present in their blood, infected people can pass the virus on to others. Approximately 5-10% of adults, 30-50% of children, and 90% of babies will not get rid of the virus and will develop chronic infection. Chronically infected people can pass the virus on to others and are at increased risk for liver problems later in life. The hepatitis B virus is 100 times more infectious than the AIDS virus. Yet, hepatitis B can be pre- vented with a safe and effective vaccine. For the 400 million people worldwide who are chronically infected with hepatitis B, the vaccine is of no use. However, there are promising new treatments for those who live with chronic hepatitis B. In the World: • This year alone, 10 to 30 million people will become infected with the hepatitis B virus (HBV). • The World Health Organization estimates that 400 million people worldwide are already chronically infected with hepatitis B.
    [Show full text]
  • Prevention & Control of Viral Hepatitis Infection
    Prevention & Control of Viral Hepatitis Infection: A Strategy for Global Action © World Health Organization 2011. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Table of contents Disease burden 02 What is viral hepatitis? 05 Prevention & control: a tailored approach 06 Global Achievements 08 Remaining challenges 10 World Health Assembly: a mandate for comprehensive prevention & control 13 WHO goals and strategy
    [Show full text]
  • Hepatitis B? HEPATITIS B Hepatitis B Is a Contagious Liver Disease That Results from Infection with the Hepatitis B Virus
    What is Hepatitis B? HEPATITIS B Hepatitis B is a contagious liver disease that results from infection with the Hepatitis B virus. When first infected, a person can develop Are you at risk? an “acute” infection, which can range in severity from a very mild illness with few or no symptoms to a serious condition requiring hospitalization. Acute Hepatitis B refers to the first 6 months after someone is exposed to the Hepatitis B virus. Some people are able to fight the infection and clear the virus. For others, the infection remains and leads to a “chronic,” or lifelong, illness. Chronic Hepatitis B refers to the illness that occurs when the Hepatitis B virus remains in a person’s body. Over time, the infection can cause serious health problems. How is Hepatitis B spread? Hepatitis B is usually spread when blood, semen, or other body fluids from a person infected with the Hepatitis B virus enter the body of someone who is not infected. This can happen through having sex with an infected partner; sharing needles, syringes, or other injection drug equipment; or from direct contact with the blood or open sores of an infected person. Hepatitis B can also be passed from an infected mother to her baby at birth. Who should be tested for Hepatitis B? Approximately 1.2 million people in the United States and 350 million people worldwide have Hepatitis B. Testing for Hepatitis B is recommended for certain groups of people, including: Most are unaware of their infection. ■ People born in Asia, Africa, and other regions with moderate or high rates Is Hepatitis B common? of Hepatitis B (see map) Yes.
    [Show full text]
  • Hepatitis A, B, and C: Learn the Differences
    Hepatitis A, B, and C: Learn the Differences Hepatitis A Hepatitis B Hepatitis C caused by the hepatitis A virus (HAV) caused by the hepatitis B virus (HBV) caused by the hepatitis C virus (HCV) HAV is found in the feces (poop) of people with hepa- HBV is found in blood and certain body fluids. The virus is spread HCV is found in blood and certain body fluids. The titis A and is usually spread by close personal contact when blood or body fluid from an infected person enters the body virus is spread when blood or body fluid from an HCV- (including sex or living in the same household). It of a person who is not immune. HBV is spread through having infected person enters another person’s body. HCV can also be spread by eating food or drinking water unprotected sex with an infected person, sharing needles or is spread through sharing needles or “works” when contaminated with HAV. “works” when shooting drugs, exposure to needlesticks or sharps shooting drugs, through exposure to needlesticks on the job, or from an infected mother to her baby during birth. or sharps on the job, or sometimes from an infected How is it spread? Exposure to infected blood in ANY situation can be a risk for mother to her baby during birth. It is possible to trans- transmission. mit HCV during sex, but it is not common. • People who wish to be protected from HAV infection • All infants, children, and teens ages 0 through 18 years There is no vaccine to prevent HCV.
    [Show full text]
  • Understanding Human Astrovirus from Pathogenesis to Treatment
    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 6-2020 Understanding Human Astrovirus from Pathogenesis to Treatment Virginia Hargest University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Diseases Commons, Medical Sciences Commons, and the Viruses Commons Recommended Citation Hargest, Virginia (0000-0003-3883-1232), "Understanding Human Astrovirus from Pathogenesis to Treatment" (2020). Theses and Dissertations (ETD). Paper 523. http://dx.doi.org/10.21007/ etd.cghs.2020.0507. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Understanding Human Astrovirus from Pathogenesis to Treatment Abstract While human astroviruses (HAstV) were discovered nearly 45 years ago, these small positive-sense RNA viruses remain critically understudied. These studies provide fundamental new research on astrovirus pathogenesis and disruption of the gut epithelium by induction of epithelial-mesenchymal transition (EMT) following astrovirus infection. Here we characterize HAstV-induced EMT as an upregulation of SNAI1 and VIM with a down regulation of CDH1 and OCLN, loss of cell-cell junctions most notably at 18 hours post-infection (hpi), and loss of cellular polarity by 24 hpi. While active transforming growth factor- (TGF-) increases during HAstV infection, inhibition of TGF- signaling does not hinder EMT induction. However, HAstV-induced EMT does require active viral replication.
    [Show full text]
  • Hepatitis B Factsheet: COVID-19 and Hep B
    Hepatitis B factsheet: COVID-19 and hep B For more information about anything in this factsheet, phone the Hepatitis Infoline on 1800 803 990 or go to www.hep.org.au COVID-19 and hep B Frequently Asked Questions (FAQ) There’s so much information swirling around these days as we deal with the changing world around us due to COVID-19. There’s lots of incorrect information and it’s easy to be overwhelmed and confused. On this page, we’ll try to clear some things up. It is important that information is helpful, clear, and checked and confirmed by experts. Please share the following information – it comes from health and medical specialists. COVID-19 is an acronym that stands for COronaVIrus Disease 2019. You might hear it called coronavirus, corona, SARS-CoV-2, or even rona. We’ll call it COVID-19 or coronavirus in this FAQ but all these terms are essentially talking about the same thing and we’ll explain them at the bottom. You’ll also hear new or unfamiliar terms like “social distancing,” “physical distancing,” “self-isolation,” and “quarantine”. These terms and what they actually mean can become confusing so we’ve including a glossary at the bottom of this FAQ. This virus has only been known about since around December 2019 so it’s all very new, information changes quickly, and we’re all learning day-by-day and week-by-week. Compare COVID-19 to hep B which we’ve known about since the 1980s and hep B even earlier in the 1960s! We’ll regularly update this page as new information comes to light.
    [Show full text]
  • Interaction Between Hepatitis B Virus and SARS-Cov-2 Infections
    World Journal of W J G Gastroenterology Submit a Manuscript: https://www.f6publishing.com World J Gastroenterol 2021 March 7; 27(9): 782-793 DOI: 10.3748/wjg.v27.i9.782 ISSN 1007-9327 (print) ISSN 2219-2840 (online) MINIREVIEWS Interaction between hepatitis B virus and SARS-CoV-2 infections Tian-Dan Xiang, Xin Zheng ORCID number: Tian-Dan Xiang Tian-Dan Xiang, Xin Zheng, Department of Infectious Diseases, Union Hospital, Tongji Medical 0000-0003-2792-6631; Xin Zheng College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, 0000-0001-6564-7807. China Author contributions: Zheng X Corresponding author: Xin Zheng, MD, PhD, Professor, Department of Infectious Diseases, contributed to the conception and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. design of the work and revised the 1277 Jiefang Avenue, Wuhan 430022, Hubei Province, China. [email protected] manuscript; Xiang TD performed the literature review and drafted the manuscript. Abstract Conflict-of-interest statement: Coronavirus disease 2019 (COVID-19) has become a global pandemic and Authors declare no conflict of garnered international attention. The causative pathogen of COVID-19 is severe interest for this article. acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel, highly contagious coronavirus. Numerous studies have reported that liver injury is quite Open-Access: This article is an common in patients with COVID-19. Hepatitis B has a worldwide distribution as open-access article that was well as in China. At present, hepatitis B virus (HBV) remains a leading cause of selected by an in-house editor and cirrhosis, liver failure, and hepatocellular carcinoma.
    [Show full text]
  • Hepatitis B Virus (HBV)
    HEPATITIS B AND COLLEGE STUDENTS Hepatitis B is a liver disease that results from infection with the Hepatitis B virus (HBV). It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis B is usually spread when blood, semen, or another body fluid from a person infected with the Hepatitis B virus enters the body of someone who is not infected. This can happen through sexual contact with an infected person or sharing needles, syringes, or other drug-injection equipment. Hepatitis B can also be passed from an infected mother to her baby at birth. Hepatitis B can be either acute or chronic. Acute HBV infection is a short-term illness that occurs within the first 6 months after someone is exposed to the Hepatitis B virus. Acute infection can — but does not always — lead to chronic infection. Chronic HBV infection is a long-term illness that occurs when the Hepatitis B virus remains in a person’s body. Chronic HBV is a serious disease that can result in long-term health problems, and even death. The best way to prevent HBV infection is by getting vaccinated. How common is hepatitis B in the United States? About 800,000 to 1.4 million persons in the United States have chronic HBV infection. Each year 38,000 more people, mostly young adults, get infected with HBV and almost 2,000 people die from chronic HBV. How is hepatitis B spread? Hepatitis B is spread when blood, semen, or other body fluid infected with the hepatitis B virus enters the body of a person who is not infected.
    [Show full text]
  • Arenaviridae Astroviridae Filoviridae Flaviviridae Hantaviridae
    Hantaviridae 0.7 Filoviridae 0.6 Picornaviridae 0.3 Wenling red spikefish hantavirus Rhinovirus C Ahab virus * Possum enterovirus * Aronnax virus * * Wenling minipizza batfish hantavirus Wenling filefish filovirus Norway rat hunnivirus * Wenling yellow goosefish hantavirus Starbuck virus * * Porcine teschovirus European mole nova virus Human Marburg marburgvirus Mosavirus Asturias virus * * * Tortoise picornavirus Egyptian fruit bat Marburg marburgvirus Banded bullfrog picornavirus * Spanish mole uluguru virus Human Sudan ebolavirus * Black spectacled toad picornavirus * Kilimanjaro virus * * * Crab-eating macaque reston ebolavirus Equine rhinitis A virus Imjin virus * Foot and mouth disease virus Dode virus * Angolan free-tailed bat bombali ebolavirus * * Human cosavirus E Seoul orthohantavirus Little free-tailed bat bombali ebolavirus * African bat icavirus A Tigray hantavirus Human Zaire ebolavirus * Saffold virus * Human choclo virus *Little collared fruit bat ebolavirus Peleg virus * Eastern red scorpionfish picornavirus * Reed vole hantavirus Human bundibugyo ebolavirus * * Isla vista hantavirus * Seal picornavirus Human Tai forest ebolavirus Chicken orivirus Paramyxoviridae 0.4 * Duck picornavirus Hepadnaviridae 0.4 Bildad virus Ned virus Tiger rockfish hepatitis B virus Western African lungfish picornavirus * Pacific spadenose shark paramyxovirus * European eel hepatitis B virus Bluegill picornavirus Nemo virus * Carp picornavirus * African cichlid hepatitis B virus Triplecross lizardfish paramyxovirus * * Fathead minnow picornavirus
    [Show full text]
  • HEPATITIS TESTING GUIDE Alegent Health Reference Laboratory
    HEPATITIS TESTING GUIDE Alegent Health Reference Laboratory Test Name NextGen Alegent Test Directory Test Description (Cerner) Orderable Name Number Order when patient has had clinical acute hepatitis of unknown origin for less than 6 months. Hepatitis Panel, Hepatitis Panel Panel includes; Hep A virus, IgM, Hepatitis Panel ARUP Acute with reflex to Hepatitis Panel, Acute with reflex Hep B virus Core antibody, IgM, Acute (0020457) HBsAg to HBsAg Confirmation Hep B virus Surface antigen with reflex to confirmation, Hep C virus antibody by CIA ARUP Order this assay when acute Hepatitis A infection is suspected. Hepatitis A Ab IgM Hep A Ab IgM Hepatitis A, IgM (0020093) Positive HAV IgM shows current or recent infection. Order only when assessing immunity for HAV from either Hepatitis A Hepatitis A Hepatitis A Virus Antibodies ARUP vaccination or previous infection. Do not use to diagnose acute antibody, total (IgG Antibody IgG & (Total) (0020591) infection. Total assay detects both IgG and IgM antibodies but and IgM IgM does not differentiate between them. Order when patient has had clinical acute hepatitis of unknown origin for less than 6 months. Positivity indicates recent Hepatitis B core Ab Hep B Core Ab Hepatitis B Virus Core Antibody, ARUP infection with hepatitis B virus, with onset < 6 months. It's IgM IgM IgM (0020092) presence indicates acute infection. In some cases, hepatitis B core IgM antibody may be the only specific marker for the diagnosis of acute infection with hepatitis B virus. This assay does not distinguish between Total B core antibody IgG and IgM detected before or at the onset of symptoms; Hepatitis B Core Hepatitis B core Hepatitis B Virus Core Antibodies ARUP however, such reactivity can persist for years after illness, and Antibody IgG & antibody (Total) (0020091) may even outlast anti-HBs.
    [Show full text]
  • Viral Hepatitis B: Introduction
    Viral Hepatitis B: Introduction “Viral hepatitis," refers to infections that affect the liver and are caused by viruses. It is a major public health issue in the United States and worldwide. Not only does viral hepatitis carry a high morbidity, but it also stresses medical resources and can have severe economic consequences. The majority of all viral hepatitis cases are preventable. Viral hepatitis includes five distinct disease entities, which are caused by at least five different viruses. Hepatitis A and hepatitis B (infectious and serum hepatitis, respectively) are considered separate diseases and both can be diagnosed by a specific serologic test. Hepatitis C and E comprise a third category, each a distinct type, with Hepatitis C parenterally transmitted, and hepatitis E enterically transmitted. Hepatitis D, or delta hepatitis, is another distinct virus that is dependent upon hepatitis B infection. This form of hepatitis may occur as a super-infectionin a hepatitis B carrier or as a co-infection in an individual with acute hepatitis B. Hepatitis viruses most often found in the United States include A, B, C, and D. Because fatality from hepatitis is relatively low, mortality figures are a poor indicator of the actual incidence of these diseases. The Centers for Disease Control and Prevention estimated that approximately 400,000–600,000 people were infected with viral hepatitis during the decade of the 1990s. Hepatitis plagued mankind as early as the fifth century BC. It was referenced in early biblical literature and described as occurring in outbreaks, especially during times of war. Toward the end of the nineteenth century, hepatitis was thought to occur as a result of infection of the hepatic parenchyma.
    [Show full text]